David Altshuler - Feb 6, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 6, 2023
Transactions value $
-$154,483
Form type
4
Date filed
2/8/2023, 03:53 PM
Previous filing
Feb 3, 2023
Next filing
Feb 14, 2023
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1.3K -100% $0.00* 0 Feb 6, 2023 Common Stock 1.3K $187.53 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $303.64 (range $303.37 to $304.27).
F4 Open market sales reported on this line occurred at a weighted average price of $305.08 (range $304.72 to $305.43).
F5 Open market sales reported on this line occurred at a weighted average price of $306.70 (range $306.32 to $307.25).
F6 Open market sales reported on this line occurred at a weighted average price of $309.06 (range $308.76 to $309.42).
F7 Fully vested.